CVS Health (NYSE: CVS) will release its latest quarterly results and provide guidance updates pre-market on Tuesday, Feb. 10. Over the past four quarters, the healthcare giant has delivered earnings results that finished well ahead of sell-side estimates. Yet even if CVS delivers a revenue and earnings beat in Q4, don’t assume that what comes next is a post-earnings rally.
Instead, it’s possible that updates to 2026 guidance, affected by the recent proposed Medicare Advantage payment rates for this year, will lead to a negative response among investors.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
This comes even as this healthcare stock has already been subject to near-term volatility on the Medicare news, falling by double-digit percentages upon its announcement late last month.
For Q4 2025, sell-side consensus calls for non-GAAP earnings of $0.99 per share. This represents a moderate decline from Q4 2024, when the company reported non-GAAP earnings of $1.19 per share. That said, walked-back expectations could give way to yet another earnings beat for CVS.
Then again, it may not be the results themselves that Wall Street focuses on with the earnings report coming next week. Instead, much as with other major healthcare stocks, investors may place greater focus on CVS’ 2026 guidance.
They may particularly be looking at the effect of the aforementioned Medicare Advantage payment rates on this guidance. UnitedHealth (NYSE: UNH), which released earnings the same day the U.S. government proposed raising Medicare Advantage payment rates by only 0.9%, released an underwhelming outlook for the coming year.
Even as CVS shares, which fell by over 14% on the Medicare Advantage news, may seem to already price in the effect of lower-than-expected payment increases on revenue and profitability, that may not necessarily be the case. That said, even if shares, which have started to bounce back from the recent sell-off, trend lower again, don’t assume this shatters CVS’ long-term bull case.
CVS shares may have sold off sharply on the Medicare Advantage news, but the company’s future prospects may be more promising than UnitedHealth’s. While UnitedHealth is primarily an insurance company, CVS’ Aetna unit makes up a smaller portion of its overall business.
